Kezar Life Sciences Cuts Workforce by 70% in Major Restructuring
Kezar Life Sciences Inc. has announced a significant restructuring plan that will cut its workforce by approximately 70%, equating to about 31 employees. This decision is part of the company's ongoing evaluation of strategic alternatives. The company anticipates incurring around $6 million in cash expenditures, mainly for severance payments and related costs, with most expenses expected to be recognized in Q4 2025. Actual costs may vary based on future developments regarding the workforce reduction.
Kezar Life Sciences Inc. has announced a major corporate reorganization, implementing a restructuring plan that will reduce its workforce by approximately 70%, or about 31 employees. The move is part of the company’s ongoing evaluation of strategic alternatives. Kezar expects to incur around $6 million in cash expenditures, primarily for one-time severance payments, benefits, and related costs, with most of these expenses recognized in the fourth quarter of 2025. The company indicated that actual costs may vary and additional charges could arise depending on future developments related to the workforce reduction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kezar Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-050671), on November 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
